Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Teeth Whitening

Medtronic's Corevalve Shows Subclavian Access Success In Patients Contraindicated For Femoral Approach
Medtronic, Inc. (NYSE: MDT) announced new data
generic viagra online
New York Times Examines Debate Surrounding Use Of Experimental Treatments In Terminally Ill Patients
Some patient advocates are lobbying to legalize "compassionate use" of experimental drugs for people with terminal illnesses who have exhausted other treatments, prompting a debate about how and when to provide such patients with treatments that could prolong their lives, the New York Times reports. Most insurers do not cover unproven treatments, and physicians have concerns that using experimental treatment could give patients false hope and cause unnecessary pain. Drugmakers are concerned that if there are unfavorable outcomes from providing patients with an unproven treatment, it could hurt the drug"s chances of receiving FDA approval. At the same time, FDA does not want to grant drugs and their makers the opportunity to skip clinical trials. Currently, patients must individually apply to receive treatments through compassionate use (Harmon, New York Times, 5/17).
plastic surgery before after
News of the day
IMPROVE Bill Seeks To Fight Medicare Fraud
Lawmakers push bill to fight Medicare fraud as part of health reform legislation.
Public Health

SNM's Clinical Trials Network Gains Added Support From Industry Leader

The SNM Clinical Trials Network, an initiative designed to address the need for streamlined drug discovery through the integration of imaging biomarkers into multi-center clinical trials, recently added Genentech, Inc. as a supporter. SNM, the world"s largest medical and scientific society for molecular imaging professionals, inaugurated the Clinical Trials Network in late 2008 to facilitate more cost-effective drug development through the integration and standardization of imaging biomarkers into Phase 1, 2, 3 and 4 therapeutic clinical trials. As part of this initiative, the society continues to bring together pharmaceutical developers, the imaging community, biomarker manufacturers and regulatory agencies to address critical needs for incorporating imaging biomarkers into multi-center trials. A formal introduction to the Clinical Trials Network was provided at a two-day workshop in Clearwater Beach, Fla. in February 2009 and additional educational sessions about the network are planned for June during SNM"s 56th Annual Meeting in Toronto, Canada. "We are gratified to have Genentech - a pioneer in the field of developing targeted therapeutics - join us in this important endeavor, which we hope will broaden the scope and effectiveness of today"s medical practice and lead to improved patient care in the near future," said Peter S. Conti, M.D., Ph.D., co-chair of the SNM Clinical Trials Network and professor of radiology, pharmacy and biomedical engineering at the University of Southern California. "We are pleased that such an innovative corporate leader supports our mission of advancing molecular imaging and therapy." The use of imaging in clinical trials can help pharmaceutical developers determine earlier in the development process whether a new product is clinically promising by allowing physicians to see and assess whether it is working as intended for a patient, explained Dr. Conti. "Molecular imaging is an essential component of such studies since it accelerates the development of promising compounds and eliminates those without apparent patient benefit earlier in the development cycle," he added. "We hope that Genentech"s collaboration with SNM will help improve patient treatment worldwide." Amy Shaw Society of Nuclear Medicine


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009